Migraine, Symbravo

New Migraine Drug Symbravo Is Now Approved by FDA for Acute Treatment
FDA approves Symbravo for acute migraine relief, combining rizatriptan and meloxicam. Discover its unique benefits and fast absorption for effective symptom control.
Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises
Axsome Therapeutics, Inc. AXSM announced that the FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults. Per the company, Symbravo, a novel,
Symbravo Approved for Acute Treatment of Migraine With or Without Aura
The Food and Drug Administration (FDA) has approved Symbravo ® (meloxicam/rizatriptan) for the acute treatment of migraine with or without aura in adults.
Redemption complete for Axsome’s Symbravo in migraine
CNS-focused biopharma Axsome Therapeutics has won US Food and Drug Administration (FDA) approval for Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.
Axsome’s Migraine Medicine Clears FDA Bar
The approval of Axsome Therapeutics’ Symbravo for migraine with or without aura came alongside the greenlight for Vertex's non-opioid treatment Journavx.
Axsome Therapeutics hosts SYMBRAVO FDA approval investor event
Axsome Therapeutics (AXSM) will host a virtual investor event and conference call at 8:00 AM Eastern Time to discuss the U.S. Food and Drug
Axsome Shares Up Post Market After Hitting Record High on FDA Approval
Shares of Axsome Therapeutics rose post-market after the company received approval for Symbravo from the Food and Drug Administration. Symbravo, for the acute treatment of migraine with or without aura in adult patients,
Axsome gets FDA approval for Symbravo for migraine
Axsome Therapeutics (NASDAQ:AXSM) has received FDA approval for its drug Symbravo for the acute treatment of migraine with or without aura in adults. Symbravo, a combination of meloxicam and rizatriptan,
Axsome Therapeutics announces FDA approval of Symbravo
Axsome Therapeutics (AXSM) announced that the U.S. FDA has approved Symbravo for the acute treatment of migraine with or without aura in
FiercePharma1d
Axsome secures hard-fought FDA nod for rapid-acting migraine drug Symbravo
Meloxicam is a nonsteroidal, anti-inflammatory molecule developed with Axsome’s Molecular Solubility Enhanced Inclusion ...
Medscape1d
FDA Clears NSAID/Triptan Combo for Migraine in Adults
The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader
The Axsome management team will provide an overview of SYMBRAVO and anticipated commercial plans. The presenters will be available to answer questions at the end of the presentation. To access the ...
MedPage Today1d
Acute Migraine Treatment Gets a New Drug
The FDA approved an oral combination of meloxicam and rizatriptan (Symbravo) to treat adults with acute migraine with or ...
Investing2d
FDA approves new migraine treatment SYMBRAVO
NEW YORK - Axsome Therapeutics, Inc. (NASDAQ:AXSM), a $5.28 billion biopharmaceutical company with impressive 51% revenue growth over the last twelve months, announced the U.S. Food and Drug ...